Form 4: KALA BIO Director Gregory Perry Receives Significant Equity Awards

KALA BIO, Inc. Director Gregory D. Perry was granted 2,450 restricted stock units and options to purchase 5,450 shares of common stock, effective June 15, 2025, as part of the company's equity incentive plan.

Summary

• Gregory D. Perry, a Director of KALA BIO, Inc. (KALA), was granted new equity awards on June 15, 2025.
• He received 2,450 Restricted Stock Units (RSUs) at a price of $0 per unit. Each RSU represents a contingent right to receive one share of KALA BIO's common stock.
• These RSUs will vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026, subject to Mr. Perry's continued service.
• Following this transaction, Mr. Perry beneficially owns 13,344 shares of common stock, which includes 6,355 unvested RSUs.
• Additionally, Mr. Perry was granted stock options to purchase 5,450 shares of common stock with an exercise price of $4.3 per share.
• These stock options also vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026.
• The stock options have an expiration date of June 14, 2035.
• Following this transaction, Mr. Perry beneficially owns 5,450 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates continued alignment of a director's interests with the company's performance through equity grants, which is a standard and generally favorable practice for corporate governance and retention.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of shareholders, as the value of these awards is directly tied to the company's stock performance.
• Equity compensation is a common and effective practice used by companies to attract and retain qualified directors and executives.

Future Outlook

The vesting schedule for the granted RSUs and stock options indicates a future commitment to the company's performance, with full vesting contingent on continued service until at least June 15, 2026, or the date of the first annual meeting of stockholders in 2026.

Industry Context

This filing reflects a standard practice within the biotechnology and pharmaceutical industries, where equity compensation is frequently used to incentivize and retain key personnel, including directors, by aligning their financial interests with the long-term success and stock performance of the company.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Gregory D. Perry, a Director of KALA BIO, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing stock value.
• Employees: While not directly impacting employees, the use of equity incentive plans can set a precedent for compensation structures across the company.

Next Steps

• The granted Restricted Stock Units (RSUs) and stock options are scheduled to vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026.

Key Dates

Keywords

KALA BIO, KALA, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Beneficial Ownership, Equity Incentive Plan